-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
"One of the findings we made after the Zika outbreak in 2015 identified a new target for yellow virus therapy, a viral protein called NS1," Dr. Watterson said.
now, for the first time, we have found that an NS1 antibody can protect against a variety of yellow viruses, including dengue, Zika and West Nile viruses.
no other antibody shows such a wide range of protections.
we have observed an unexpected improvement in the protective effect of this antibody compared to existing treatments.
" estimates that 390 million people worldwide are infected with dengue virus each year, especially in tropical and subtropical regions.
of these cases, about half a million develop more severe forms of dengue fever, which can be fatal.
Watterson said the findings are important because developing vaccines against viruses such as dengue is an unsolt global challenge.
development of vaccines and therapies has been greatly hampered because antibodies against major viral envelope proteins can also increase the severity of the disease, " he said.
this phenomenon is known as antibody dependence enhancement (ADE) and leads to complications from the large-scale roll-out of the first licensed dengue vaccine.
, however, because NS1 antibodies do not cause ADE, our results provide a blueprint for developing new and safe broad-spectrum vaccines for a variety of yellow viruses, including dengue viruses.
," Dr. Modhira said, and the antibody could also provide the first line of defense in future global outbreaks.
antibody binds to a variety of yellow viruses, including the Usuto virus in Europe and the Rocio and Ilheus viruses in South America," he said.
these viruses have caused outbreaks in the past.
Young says his team first developed these antibodies more than 30 years ago.
years, these antibodies have provided a lot of insight into the biological properties of dengue fever and have been used to develop diagnostic methods," he said.
pleased to see that they are now making progress as potential templates for therapeutic drugs.
highlights the critical importance of discovery research in providing a basis for transformation into clinical practice.
" Reference: 1.Naphak Modhiran et al. A broadly protective antibody that targets the flavivirus NS1 protein. Science, 2021, doi:10.1126/science.abb9425. 2.New defense against dengue and emerging mosquito-borne viruses